A Comparison of Retrospective Database Analysis with Chart Review in Patients Receiving Somatostatin Analog (SSA) in Neuroendocrine Tumors (NETs) Abstract #2160

Introduction: SSAs are recommended for the treatment of locoregional/metastatic NET.
Aim(s): The objective of this study was to understand SSA dose/frequency patterns using claims data vs patient (pt) chart data in the US after the approval of lanreotide depot (LAN) in the US for gastrointestinal (GI) and pancreatic NET.
Materials and methods: This analysis examined a subgroup of pts from an existing patient-level US claims data set (1/2015-12/2016) then compared to additional physician-reported clinical data. Physicians of pts (108 LAN; 440 octreotide LAR (OCT)) in the claims analysis were asked to complete chart reviews. Pts identified with metastatic NET (lung, GI or pancreatic) were indexed at the earliest initiation of treatment with an SSA. Treatment patterns and dosing/frequency of SSAs were described from NET diagnosis through treatment change.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: David Ray

To read results and conclusion, please login ...

Further abstracts you may be interested in

#21 Peptide Receptor Radioligand Therapy (PRRT) is an Effective Treatment for the Long-Term Stabilization of Malignant Gastrinomas
Introduction: Gastrinomas represent a rare group of neuroendocrine tumors usually located in the duodenum or pancreas. They secrete gastrin, which is responsible for the clinical picture of severe acid-related peptic disease and diarrhea, known as the Zollinger-Ellison syndrome (ZES). While symptomatic control may be achieved with proton-pump inhibitors (PPIs) and somatostatin analogues (SSAs) treatment, little data is known regarding the possible anti-tumor effect of the peptide receptor radioligand therapy (PRRT) in gastrinoma patients.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Simona Grozinsky-Glasberg
#118 Gastrointestinal motility in patients with neuroendocrine tumors
Introduction: Diarrhea is the most common symptom in patients with intestinal neuroendocrine tumors (NET). Somatostatin analogues reduce stool frequency and may increase gastrointestinal transit time (GITT). Motility tracking system® MTS-1 (MTS) (Motilis, Switzerland) is a novel, safe, almost non-invasive and easy-to-perform method for description of gastrointestinal motility.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Tine Gregersen
#130 Lanreotide Autogel for malignant carcinoid syndrome: an 8-year experience
Introduction: Somatostatin analogues provide symptomatic relief in carcinoid syndrome and recently have been shown to inhibit tumor growth in metastatic gastroenteropancreatic neuroendocrine tumors (NETs). Lanreotide compounds are reported to have similar efficacy to Octreotide compounds. There is limited long-term data available on Lanreoitde Autogel.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohid S Khan
#131 Efficacy and safety results from a Phase II study of pasireotide (SOM230) in the treatment of patients with metastatic NETs refractory or resistant to octreotide LAR
Introduction: Pasireotide, a multi-receptor targeted somatostatin analogue, has 30-, 5- and 39-fold greater affinity for sst1,3 and sst5 receptors, respectively, and a slightly lower affinity for sst2, than octreotide. Because of this multi-receptor binding profile, pasireotide may be effective in controlling symptoms of carcinoid syndrome in patients with gastroenteropancreatic neuroendocrine tumors (NETs) who are no longer responsive to currently available somatostatin analogues.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Larry K Kvols
#796 Somatostatin Analogues for Preventing Carcinoid Crisis
Introduction: Carcinoid crisis is a life-threating syndrome of neuroendocrine tumors (NETs) and is characterized by dramatic blood pressure fluctuation, arrhythmias, and bronchospasm. Somatostatin analogues (SSTA) have been recommended for prophylactic administration before provocative procedures.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: LinJie Guo
Authors: Guo L, Tang C, ...